SEC Info - Kintara Therapeutics, Inc. - ‘S-1/A’ on 7/11/19

Kintara Therapeutics, Inc. – ‘S-1/A’ on 7/11/19 – ‘R44’

On: Thursday, 7/11/19, at 4:17pm ET · Accession #: 1213900-19-12524 · File #: 333-232332

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/11/19 DelMar Pharmaceuticals, Inc. S-1/A 71:7.9M Edgar Agents LLC/FA

Document/Exhibit Description Pages Size 1: S-1/A Amendment No. 1 to Form S-1 HTML 1.11M 2: EX-23.1 Consent of Ernst & Young, LLP HTML 19K 9: R1 Document and Entity Information HTML 34K 10: R2 Consolidated Condensed Interim Balance Sheets HTML 90K 11: R3 Consolidated Condensed Interim Balance Sheets HTML 41K (Parenthetical) 12: R4 Consolidated Condensed Interim Statements of Loss HTML 63K and Comprehensive Loss 13: R5 Consolidated Statements of Changes in HTML 112K Stockholders' Equity 14: R6 Consolidated Condensed Interim Statements of Cash HTML 84K Flows 15: R7 Going Concern, Nature of Operations, and Corporate HTML 40K History 16: R8 Significant Accounting Policies HTML 81K 17: R9 Valent Technologies, LLC HTML 28K 18: R10 Derivative Liability HTML 61K 19: R11 Stockholders' Equity HTML 227K 20: R12 Financial Instruments HTML 36K 21: R13 Related Party Transactions HTML 22K 22: R14 Current and Deferred Income Taxes HTML 37K 23: R15 Commitments and Contingencies HTML 25K 24: R16 Supplementary Statement of Cash Flows Information HTML 31K 25: R17 Financial Risk Management HTML 34K 26: R18 Subsequent Events HTML 32K 27: R19 Significant Accounting Policies (Policies) HTML 129K 28: R20 Significant Accounting Policies (Tables) HTML 25K 29: R21 Derivative Liability (Tables) HTML 57K 30: R22 Stockholders' Equity (Tables) HTML 202K 31: R23 Financial Instruments (Tables) HTML 28K 32: R24 Current and Deferred Income Taxes (Tables) HTML 47K 33: R25 Supplementary Statement of Cash Flows Information HTML 30K (Tables) 34: R26 Financial Risk Management (Tables) HTML 33K 35: R27 Going Concern, Nature of Operations, and Corporate HTML 37K History (Details) 36: R28 Significant Accounting Policies (Details) HTML 30K 37: R29 Significant Accounting Policies (Details Textual) HTML 45K 38: R30 Valent Technologies, LLC (Details) HTML 49K 39: R31 Derivative Liability (Details) HTML 37K 40: R32 Derivative Liability (Details 1) HTML 41K 41: R33 Derivative Liability (Details Textual) HTML 71K 42: R34 Stockholders' Equity (Details) HTML 100K 43: R35 Stockholders' Equity (Details 1) HTML 30K 44: R36 Stockholders' Equity (Details 2) HTML 37K 45: R37 Stockholders' Equity (Details 3) HTML 40K 46: R38 Stockholders' Equity (Details 4) HTML 118K 47: R39 Stockholders' Equity (Details 5) HTML 38K 48: R40 Stockholders' Equity (Details 6) HTML 30K 49: R41 Stockholders' Equity (Details 7) HTML 51K 50: R42 Stockholders' Equity (Details 8) HTML 35K 51: R43 Stockholders' Equity (Details 9) HTML 58K 52: R44 Stockholders' Equity (Details 10) HTML 90K 53: R45 Stockholders' Equity (Details 11) HTML 33K 54: R46 Financial Instruments (Details) HTML 28K 55: R47 Related Party Transactions (Details) HTML 23K 56: R48 Current and Deferred Income Taxes (Details) HTML 47K 57: R49 Current and Deferred Income Taxes (Details 1) HTML 44K 58: R50 Current and Deferred Income Taxes (Details HTML 46K Textual) 59: R51 Commitments and Contingencies (Details) HTML 27K 60: R52 Stockholders' Equity (Details Textual) HTML 91K 61: R53 Stockholders' Equity (Details Textual 1) HTML 66K 62: R54 Stockholders' Equity (Details Textual 2) HTML 52K 63: R55 Stockholders' Equity (Details Textual 3) HTML 46K 64: R56 Supplementary Statement of Cash Flows Information HTML 43K (Details) 65: R57 Financial Risk Management (Details) HTML 27K 66: R58 Financial Risk Management (Details 1) HTML 28K 67: R59 Financial Risk Management (Details Textual) HTML 48K 68: R60 Subsequent Events (Details) HTML 51K 70: XML IDEA XML File -- Filing Summary XML 133K 69: EXCEL IDEA Workbook of Financial Reports XLSX 101K 3: EX-101.INS XBRL Instance -- dmpi-20190331 XML 2.20M 5: EX-101.CAL XBRL Calculations -- dmpi-20190331_cal XML 142K 6: EX-101.DEF XBRL Definitions -- dmpi-20190331_def XML 703K 7: EX-101.LAB XBRL Labels -- dmpi-20190331_lab XML 1.14M 8: EX-101.PRE XBRL Presentations -- dmpi-20190331_pre XML 897K 4: EX-101.SCH XBRL Schema -- dmpi-20190331 XSD 211K 71: ZIP XBRL Zipped Folder -- 0001213900-19-012524-xbrl Zip 171K

Stockholders' Equity (Details 10) - $ / shares

9 Months Ended

12 Months Ended

Mar. 31, 2019

Jun. 30, 2018

Jun. 30, 2017

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price

$ 1,000

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number

862,503

1,428,128

662,891

Exercise price

$ 24.80

$ 20.80

Warrant [Member] | Issued For Services One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number

6,000

Exercise price

$ 17.80

$ 17.8

This ‘S-1/A’ Filing	Date	Other Filings

	9/15/23
	2/27/23
	1/25/23
	9/22/22
	9/20/22
	4/19/22
	4/12/22
	10/11/21
	6/8/21
	5/12/21
	2/1/21
	7/31/20	CORRESP, UPLOAD
	7/15/20
	7/1/20	S-4/A
	2/27/20
Filed on:	7/11/19	CORRESP
	6/30/19	10-K
	3/31/19	10-Q
	9/12/18
	6/30/18	10-K
	6/30/17	10-K, 4
		List all Filings

Kintara Therapeutics, Inc. – ‘S-1/A’ on 7/11/19 – ‘R44’

On: Thursday, 7/11/19, at 4:17pm ET · Accession #: 1213900-19-12524 · File #: 333-232332

Previous ‘S-1’: ‘S-1’ on 6/25/19 · Next: ‘S-1’ on 8/1/19 · Latest: ‘S-1/A’ on 10/27/23

Pre-Effective Amendment to Registration Statement (General Form) — Form S-1Filing Table of Contents

‘R44’ — Stockholders’ Equity (Details 10)

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Pre-Effective Amendment to Registration Statement (General Form) — Form S-1
Filing Table of Contents